News Archive
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors
We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
GeekWire
July 18, 2024
Media
Bonum Therapeutics to double its space in Eastlake after move
Puget Sound Business Journal
July 21, 2024
Media
Bonum Therapeutics to Present Posters and a Short Talk on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference
“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”
Bonum Therapeutics to Present Lead Program at AACR
“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”